Đa ung thư nguyên phát trên một bệnh nhân

Multiple primary malignancies (MPMs) represent a significant and growing challenge in oncology, characterized by the development of two or more distinct primary cancers in the same individual. The complexity associated with accurate diagnosis, precise staging, differentiation from metastatic disease, and the selection of optimal treatment strategies poses considerable hurdles for clinicians. This paper addresses these critical issues by revisiting the pathogenesis, epidemiology, and therapeutic approaches for MPMs, drawing insights from clinical cases managed at Tam Anh General Hospital. Understanding these intricate aspects is crucial for improving patient outcomes in this challenging clinical scenario.

Các bác sĩ lâm sàng, nhà nghiên cứu ung thư, sinh viên y khoa và các chuyên gia y tế quan tâm đến bệnh học ung thư đa nguyên phát và phương pháp điều trị.

This academic manuscript comprehensively explores the intricate landscape of multiple primary malignancies (MPMs), defined as the occurrence of two or more primary cancers. It highlights the diagnostic and therapeutic complexities faced by clinicians, particularly in distinguishing primary tumors from metastatic lesions and tailoring individualized treatment plans. The paper presents an analysis of three diverse đa ung thư nguyên phát cases from Tam Anh General Hospital, illustrating varied presentations ranging from hepatocellular carcinoma (HCC) with lung cancer, and rectal cancer post-gastric cancer, to coexistent breast and colorectal cancers. We discuss the epidemiology, noting prevalence rates from 2% to 17%, and delve into key risk factors including genetic predispositions (BRCA1/2, POLE/POLD1, TP53), prior cancer therapies, environmental exposures, and lifestyle factors. The role of dấu ấn sinh học (e.g., AFP, CA19-9, MSI/MMR) and advanced molecular techniques (e.g., ctDNA, genetic mutations) is emphasized as increasingly pivotal for precise diagnosis. Treatment strategies necessitate personalized, multimodal approaches, potentially utilizing targeted therapies or immunotherapies based on shared genetic profiles. The paper underscores the imperative for close multidisciplinary coordination in managing these patients and concludes that advancements in precision medicine, genetic technologies, and integrated therapies are vital for enhancing prognosis and quality of life for individuals with MPMs, whether synchronous or metachronous.